Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Does enoxaparin (40 mg) prevent deep-vein thrombosis compared to standard unfractionated heparin in high-risk hospitalized medical patients?
Enoxaparin is an effective and safer alternative to standard unfractionated heparin for DVT prophylaxis in high-risk hospitalized medical patients.
Tasa de eventos absoluta: 0% vs 0%
In a multicentre, randomized, double-blind controlled trial comparing the low-molecular-weight heparin enoxaparin (40 mg) with a standard unfractionated heparin (Ca-heparin, 3 × 5,000 U) in deep-vein thrombosis prophylaxis in a high-risk group of 959 hospitalized medical patients, enoxaparin was at least as efficacious as standard heparin, with fewer adverse events.
Lechler et al. (Tue,) reported a other. Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: